CovidChloroV1, Main, Exploration, bibRecord, 001400

Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak.

Identifieur interne : 001400 ( Main/Exploration ); précédent : 001399; suivant : 001401

Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak.

Auteurs : Zheng Yao Low [Malaisie] ; Isra Ahmad Farouk [Malaisie] ; Sunil Kumar Lal [Malaisie]

Source :

Viruses [ 1999-4915 ] ; 2020.

RBID : pubmed:32972027

Descripteurs français

KwdFr :
- Betacoronavirus (MeSH), Humains (MeSH), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (épidémiologie), Maladies rares (traitement médicamenteux), Médecine de précision (MeSH), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (épidémiologie), Recherche pharmaceutique (MeSH), Repositionnement des médicaments (tendances), Repositionnement des médicaments (économie).
MESH :
- tendances : Repositionnement des médicaments.
- traitement médicamenteux : Infections à coronavirus, Maladies rares, Pneumopathie virale.
- économie : Repositionnement des médicaments.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- Betacoronavirus, Humains, Médecine de précision, Pandémies, Recherche pharmaceutique.

English descriptors

KwdEn :
- Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Drug Repositioning (economics), Drug Repositioning (trends), Humans (MeSH), Pandemics (MeSH), Pharmaceutical Research (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Precision Medicine (MeSH), Rare Diseases (drug therapy), SARS-CoV-2 (MeSH).
MESH :
- drug therapy : Coronavirus Infections, Pneumonia, Viral, Rare Diseases.
- economics : Drug Repositioning.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- trends : Drug Repositioning.
- Betacoronavirus, COVID-19, Humans, Pandemics, Pharmaceutical Research, Precision Medicine, SARS-CoV-2.

Abstract

Traditionally, drug discovery utilises a de novo design approach, which requires high cost and many years of drug development before it reaches the market. Novel drug development does not always account for orphan diseases, which have low demand and hence low-profit margins for drug developers. Recently, drug repositioning has gained recognition as an alternative approach that explores new avenues for pre-existing commercially approved or rejected drugs to treat diseases aside from the intended ones. Drug repositioning results in lower overall developmental expenses and risk assessments, as the efficacy and safety of the original drug have already been well accessed and approved by regulatory authorities. The greatest advantage of drug repositioning is that it breathes new life into the novel, rare, orphan, and resistant diseases, such as Cushing's syndrome, HIV infection, and pandemic outbreaks such as COVID-19. Repositioning existing drugs such as Hydroxychloroquine, Remdesivir, Ivermectin and Baricitinib shows good potential for COVID-19 treatment. This can crucially aid in resolving outbreaks in urgent times of need. This review discusses the past success in drug repositioning, the current technological advancement in the field, drug repositioning for personalised medicine and the ongoing research on newly emerging drugs under consideration for the COVID-19 treatment.

DOI: 10.3390/v12091058
PubMed: 32972027
PubMed Central: PMC7551028

Affiliations:

Malaisie

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000B52
to stream Main, to step Curation: 000B52

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak.</title>
<author><name sortKey="Low, Zheng Yao" sort="Low, Zheng Yao" uniqKey="Low Z" first="Zheng Yao" last="Low">Zheng Yao Low</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Science, Monash University, Bandar Sunway, Subang Jaya 47500, Selangor Darul Ehsan, Malaysia.</nlm:affiliation>
<country xml:lang="fr">Malaisie</country>
<wicri:regionArea>School of Science, Monash University, Bandar Sunway, Subang Jaya 47500, Selangor Darul Ehsan</wicri:regionArea>
<wicri:noRegion>Selangor Darul Ehsan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Farouk, Isra Ahmad" sort="Farouk, Isra Ahmad" uniqKey="Farouk I" first="Isra Ahmad" last="Farouk">Isra Ahmad Farouk</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Science, Monash University, Bandar Sunway, Subang Jaya 47500, Selangor Darul Ehsan, Malaysia.</nlm:affiliation>
<country xml:lang="fr">Malaisie</country>
<wicri:regionArea>School of Science, Monash University, Bandar Sunway, Subang Jaya 47500, Selangor Darul Ehsan</wicri:regionArea>
<wicri:noRegion>Selangor Darul Ehsan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lal, Sunil Kumar" sort="Lal, Sunil Kumar" uniqKey="Lal S" first="Sunil Kumar" last="Lal">Sunil Kumar Lal</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Science, Monash University, Bandar Sunway, Subang Jaya 47500, Selangor Darul Ehsan, Malaysia.</nlm:affiliation>
<country xml:lang="fr">Malaisie</country>
<wicri:regionArea>School of Science, Monash University, Bandar Sunway, Subang Jaya 47500, Selangor Darul Ehsan</wicri:regionArea>
<wicri:noRegion>Selangor Darul Ehsan</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Tropical Medicine & Biology Platform, Monash University, Subang Jaya 47500, Selangor Darul Ehsan, Malaysia.</nlm:affiliation>
<country xml:lang="fr">Malaisie</country>
<wicri:regionArea>Tropical Medicine & Biology Platform, Monash University, Subang Jaya 47500, Selangor Darul Ehsan</wicri:regionArea>
<wicri:noRegion>Selangor Darul Ehsan</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32972027</idno>
<idno type="pmid">32972027</idno>
<idno type="doi">10.3390/v12091058</idno>
<idno type="pmc">PMC7551028</idno>
<idno type="wicri:Area/Main/Corpus">000B52</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000B52</idno>
<idno type="wicri:Area/Main/Curation">000B52</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000B52</idno>
<idno type="wicri:Area/Main/Exploration">000B52</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak.</title>
<author><name sortKey="Low, Zheng Yao" sort="Low, Zheng Yao" uniqKey="Low Z" first="Zheng Yao" last="Low">Zheng Yao Low</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Science, Monash University, Bandar Sunway, Subang Jaya 47500, Selangor Darul Ehsan, Malaysia.</nlm:affiliation>
<country xml:lang="fr">Malaisie</country>
<wicri:regionArea>School of Science, Monash University, Bandar Sunway, Subang Jaya 47500, Selangor Darul Ehsan</wicri:regionArea>
<wicri:noRegion>Selangor Darul Ehsan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Farouk, Isra Ahmad" sort="Farouk, Isra Ahmad" uniqKey="Farouk I" first="Isra Ahmad" last="Farouk">Isra Ahmad Farouk</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Science, Monash University, Bandar Sunway, Subang Jaya 47500, Selangor Darul Ehsan, Malaysia.</nlm:affiliation>
<country xml:lang="fr">Malaisie</country>
<wicri:regionArea>School of Science, Monash University, Bandar Sunway, Subang Jaya 47500, Selangor Darul Ehsan</wicri:regionArea>
<wicri:noRegion>Selangor Darul Ehsan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lal, Sunil Kumar" sort="Lal, Sunil Kumar" uniqKey="Lal S" first="Sunil Kumar" last="Lal">Sunil Kumar Lal</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Science, Monash University, Bandar Sunway, Subang Jaya 47500, Selangor Darul Ehsan, Malaysia.</nlm:affiliation>
<country xml:lang="fr">Malaisie</country>
<wicri:regionArea>School of Science, Monash University, Bandar Sunway, Subang Jaya 47500, Selangor Darul Ehsan</wicri:regionArea>
<wicri:noRegion>Selangor Darul Ehsan</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Tropical Medicine & Biology Platform, Monash University, Subang Jaya 47500, Selangor Darul Ehsan, Malaysia.</nlm:affiliation>
<country xml:lang="fr">Malaisie</country>
<wicri:regionArea>Tropical Medicine & Biology Platform, Monash University, Subang Jaya 47500, Selangor Darul Ehsan</wicri:regionArea>
<wicri:noRegion>Selangor Darul Ehsan</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Viruses</title>
<idno type="eISSN">1999-4915</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Drug Repositioning (economics)</term>
<term>Drug Repositioning (trends)</term>
<term>Humans (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pharmaceutical Research (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Precision Medicine (MeSH)</term>
<term>Rare Diseases (drug therapy)</term>
<term>SARS-CoV-2 (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Betacoronavirus (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Maladies rares (traitement médicamenteux)</term>
<term>Médecine de précision (MeSH)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Recherche pharmaceutique (MeSH)</term>
<term>Repositionnement des médicaments (tendances)</term>
<term>Repositionnement des médicaments (économie)</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
<term>Rare Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Drug Repositioning</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Repositionnement des médicaments</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Maladies rares</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Drug Repositioning</term>
</keywords>
<keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Repositionnement des médicaments</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Humans</term>
<term>Pandemics</term>
<term>Pharmaceutical Research</term>
<term>Precision Medicine</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term>
<term>Humains</term>
<term>Médecine de précision</term>
<term>Pandémies</term>
<term>Recherche pharmaceutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Traditionally, drug discovery utilises a de novo design approach, which requires high cost and many years of drug development before it reaches the market. Novel drug development does not always account for orphan diseases, which have low demand and hence low-profit margins for drug developers. Recently, drug repositioning has gained recognition as an alternative approach that explores new avenues for pre-existing commercially approved or rejected drugs to treat diseases aside from the intended ones. Drug repositioning results in lower overall developmental expenses and risk assessments, as the efficacy and safety of the original drug have already been well accessed and approved by regulatory authorities. The greatest advantage of drug repositioning is that it breathes new life into the novel, rare, orphan, and resistant diseases, such as Cushing's syndrome, HIV infection, and pandemic outbreaks such as COVID-19. Repositioning existing drugs such as Hydroxychloroquine, Remdesivir, Ivermectin and Baricitinib shows good potential for COVID-19 treatment. This can crucially aid in resolving outbreaks in urgent times of need. This review discusses the past success in drug repositioning, the current technological advancement in the field, drug repositioning for personalised medicine and the ongoing research on newly emerging drugs under consideration for the COVID-19 treatment.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32972027</PMID>
<DateCompleted><Year>2020</Year>
<Month>10</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>12</Volume>
<Issue>9</Issue>
<PubDate><Year>2020</Year>
<Month>09</Month>
<Day>22</Day>
</PubDate>
</JournalIssue>
<Title>Viruses</Title>
<ISOAbbreviation>Viruses</ISOAbbreviation>
</Journal>
<ArticleTitle>Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">E1058</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.3390/v12091058</ELocationID>
<Abstract><AbstractText>Traditionally, drug discovery utilises a de novo design approach, which requires high cost and many years of drug development before it reaches the market. Novel drug development does not always account for orphan diseases, which have low demand and hence low-profit margins for drug developers. Recently, drug repositioning has gained recognition as an alternative approach that explores new avenues for pre-existing commercially approved or rejected drugs to treat diseases aside from the intended ones. Drug repositioning results in lower overall developmental expenses and risk assessments, as the efficacy and safety of the original drug have already been well accessed and approved by regulatory authorities. The greatest advantage of drug repositioning is that it breathes new life into the novel, rare, orphan, and resistant diseases, such as Cushing's syndrome, HIV infection, and pandemic outbreaks such as COVID-19. Repositioning existing drugs such as Hydroxychloroquine, Remdesivir, Ivermectin and Baricitinib shows good potential for COVID-19 treatment. This can crucially aid in resolving outbreaks in urgent times of need. This review discusses the past success in drug repositioning, the current technological advancement in the field, drug repositioning for personalised medicine and the ongoing research on newly emerging drugs under consideration for the COVID-19 treatment.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Low</LastName>
<ForeName>Zheng Yao</ForeName>
<Initials>ZY</Initials>
<Identifier Source="ORCID">0000-0001-6213-6040</Identifier>
<AffiliationInfo><Affiliation>School of Science, Monash University, Bandar Sunway, Subang Jaya 47500, Selangor Darul Ehsan, Malaysia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Farouk</LastName>
<ForeName>Isra Ahmad</ForeName>
<Initials>IA</Initials>
<AffiliationInfo><Affiliation>School of Science, Monash University, Bandar Sunway, Subang Jaya 47500, Selangor Darul Ehsan, Malaysia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lal</LastName>
<ForeName>Sunil Kumar</ForeName>
<Initials>SK</Initials>
<Identifier Source="ORCID">0000-0003-3548-4853</Identifier>
<AffiliationInfo><Affiliation>School of Science, Monash University, Bandar Sunway, Subang Jaya 47500, Selangor Darul Ehsan, Malaysia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Tropical Medicine & Biology Platform, Monash University, Subang Jaya 47500, Selangor Darul Ehsan, Malaysia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>09</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Viruses</MedlineTA>
<NlmUniqueID>101509722</NlmUniqueID>
<ISSNLinking>1999-4915</ISSNLinking>
</MedlineJournalInfo>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000071220" MajorTopicYN="N">Pharmaceutical Research</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D035583" MajorTopicYN="N">Rare Diseases</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">Cushing’s syndrome</Keyword>
<Keyword MajorTopicYN="Y">HIV</Keyword>
<Keyword MajorTopicYN="Y">drug personalisation</Keyword>
<Keyword MajorTopicYN="Y">drug repositioning</Keyword>
<Keyword MajorTopicYN="Y">novel diseases</Keyword>
<Keyword MajorTopicYN="Y">orphan diseases</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>07</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>08</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>08</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>9</Month>
<Day>25</Day>
<Hour>1</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>9</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32972027</ArticleId>
<ArticleId IdType="pii">v12091058</ArticleId>
<ArticleId IdType="doi">10.3390/v12091058</ArticleId>
<ArticleId IdType="pmc">PMC7551028</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Clin Med. 2019 Nov 12;8(11):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31726770</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Drug Discov. 2015;10(9):937-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26088126</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Microbiol Infect Dis. 2020 Sep;39(9):1629-1635</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32333222</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2004 Aug;3(8):673-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15286734</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Med Inform Assoc. 2017 May 1;24(3):614-618</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27678460</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioinformatics. 2019 Aug 15;35(16):2818-2826</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30624606</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Pharm Sin B. 2020 May;10(5):766-788</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32292689</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2009 Nov 12;462(7270):175-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19881490</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Brief Bioinform. 2011 Jul;12(4):357-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21712342</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2014 Feb;13(2):85-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24481294</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chem Inf Model. 2015 Feb 23;55(2):263-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25635324</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2016 Dec;88(12):2170-2178</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27183377</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Discov Today. 2017 Feb;22(2):210-222</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27693712</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Discov Today. 2014 May;19(5):637-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24239728</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2006 Oct;10(4):331-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17010674</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann N Y Acad Sci. 1991;615:125-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2039137</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Pharmacol. 2018 Sep 20;9:1068</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30294274</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2008 Aug 23;372(9639):657-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18722871</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Cutan Med Surg. 2009 Mar;28(1):19-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19341939</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Proteome Res. 2017 Apr 7;16(4):1401-1409</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28264154</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cells. 2019 Jan 11;8(1):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30642011</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2007 Aug 9;448(7154):645-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17687303</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacol Ther. 2020 Aug;108(2):242-247</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32246834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gene Rep. 2020 Jun;19:100682</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32300673</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2002 Sep;1(9):663-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12216576</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Discov Today. 2014 Dec;19(12):1841-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25269415</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2019 Jan 24;9(1):523</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30679503</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2010 Aug 04;(8):CD008651</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20687097</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Discov Today. 2012 Dec;17(23-24):1289-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22889966</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Clin Oncol. 2015 Dec;12(12):732-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26483297</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 Apr 22;369:m1610</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32321732</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Cent Sci. 2020 May 27;6(5):672-683</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32483554</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):e30-e31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32032529</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Med Genomics. 2015;8 Suppl 2:S1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26044129</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>mBio. 2020 May 22;11(3):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32444382</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Acad Dermatol. 2008 Oct;59(4):547-66; quiz 567-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18793935</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2011 Dec 01;10(12):897-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22129984</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Med Chem Lett. 2012 May 24;3(6):442-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24900492</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharmacol Sci. 2017 Nov;135(3):114-120</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29132796</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Psychosomatics. 2004 Jan-Feb;45(1):17-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14709757</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Jpn J Infect Dis. 2017 Nov 22;70(6):647-655</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29093313</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neuropsychiatr Dis Treat. 2016 Aug 25;12:2165-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27601910</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Ther. 1993 Feb-Mar;57(2-3):203-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8361993</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Dermatol Res. 2020 Apr;312(3):213-221</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31501921</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Dermatol. 1988 Mar;124(3):322-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3345081</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2019 Jan;18(1):41-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30310233</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Cheminform. 2013 Jun 22;5(1):30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23800010</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatrics. 2001 Jun;107(6):E105</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11389303</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Biol Sci. 2014 Jun 10;10(7):654-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25013375</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ther Clin Risk Manag. 2012;8:267-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22767991</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2012 Aug 9;55(15):6832-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22780961</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br Med J. 1977 Sep 10;2(6088):667-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">902045</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Sep;84(18):9301-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20610712</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2012 Mar 01;11(3):191-200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22378269</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AIDS. 2011 Jul 17;25(11):1347-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21505294</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JCI Insight. 2020 Feb 13;5(3):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32051340</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pathol Res Pract. 2019 Jun;215(6):152378</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30871913</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trop Med Int Health. 2020 Mar;25(3):278-280</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32052514</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Transl Med. 2016 Sep 20;14:269</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27646033</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Discov Today. 2016 Jul;21(7):1189-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27240777</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2017 Aug 9;12(8):e0180939</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28792952</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2020 Jun;178:104787</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32251768</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2011 Jun 24;10(7):475-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21701499</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Life Sci. 2020 Jul 15;253:117592</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32222463</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Brief Bioinform. 2011 Jul;12(4):346-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21504985</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Comput Aided Drug Des. 2011 Jun;7(2):146-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21534921</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gastric Cancer. 2018 Mar;18(1):1-19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29629216</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Dermatol. 2004 Feb;150(2):186-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14996087</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Discov Today Ther Strateg. 2011 Winter;8(3-4):61-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22368688</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>One Health. 2020 Mar 27;9:100128</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32258351</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Clin Oncol. 2010 Jul;7(7):401-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20551945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Pharmacol Sci. 2013 May;34(5):267-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23582281</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2017 Jan 4;45(D1):D932-D939</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27789690</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Toxicol Sci. 2011 Jul;122(1):1-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21507989</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Bioinformatics. 2019 Dec 16;20(Suppl 26):628</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31839008</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Res Ther. 2020 Jan 23;22(1):16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31973752</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2013 May;57(5):2029-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23403423</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chem Inf Model. 2020 Jun 22;60(6):3277-3286</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32315171</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Intern Med. 2006 Jul;260(1):1-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16789973</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(3):e33174</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22432004</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1974 Dec;71(12):4980-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4531031</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11865-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8876229</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Biotechnol. 2012 Apr 10;30(4):317-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22491277</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Biotechnol. 2020 Apr;38(4):379-381</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205870</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2014 Jun;20(6):590-1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24901567</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Brief Bioinform. 2011 Jul;12(4):341-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21357612</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cold Spring Harb Perspect Med. 2012 Apr;2(4):a007161</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22474613</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2003 Nov;3(11):722-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14592603</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Biol Sci. 2018 Jul 13;14(10):1232-1244</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30123072</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2014 Jan 17;343(6168):256-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24436409</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Brief Bioinform. 2011 Jul;12(4):303-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21690101</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2006 May 4;49(9):2845-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16640347</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Malaisie</li>
</country>
</list>
<tree><country name="Malaisie"><noRegion><name sortKey="Low, Zheng Yao" sort="Low, Zheng Yao" uniqKey="Low Z" first="Zheng Yao" last="Low">Zheng Yao Low</name>
</noRegion>
<name sortKey="Farouk, Isra Ahmad" sort="Farouk, Isra Ahmad" uniqKey="Farouk I" first="Isra Ahmad" last="Farouk">Isra Ahmad Farouk</name>
<name sortKey="Lal, Sunil Kumar" sort="Lal, Sunil Kumar" uniqKey="Lal S" first="Sunil Kumar" last="Lal">Sunil Kumar Lal</name>
<name sortKey="Lal, Sunil Kumar" sort="Lal, Sunil Kumar" uniqKey="Lal S" first="Sunil Kumar" last="Lal">Sunil Kumar Lal</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001400 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001400 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32972027
   |texte=   Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32972027" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak.

Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki